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Abstract
Introduction: Few cases of Epstein-Barr virus myelitis have been described in the literature. Multi-centric
Castleman’s disease is a lymphoproliferative disorder that is well known for its associations with the human
immunodeficiency virus, human herpes virus 8, and Kaposi’s sarcoma. The concurrent presentation of these two
diseases in a patient at the same time is extremely unusual.
Case Presentation: We describe the case of a 43-year-old Caucasian man with acquired immune deficiency
syndrome who presented with fever, weight loss and diffuse lymphadenopathy, and was diagnosed with multi-
centric Castleman’s disease. He presented three weeks later with lower extremity weakness and urinary retention,
at which time cerebrospinal fluid contained lymphocytic pleocytosis and elevated protein. Magnetic resonance
imaging demonstrated abnormal spinal cord signal intensity over several cervical and thoracic segments,
suggesting the diagnosis of myelitis. Our patient was ultimately diagnosed with Epstein-Barr virus myelitis, as
Epstein-Barr virus DNA was detected by polymerase chain reaction in the cerebrospinal fluid.
Conclusion: To the best of our knowledge, this is the first case of multi-centric Castleman’s disease followed by
acute Epstein-Barr virus myelitis in a human immunodeficiency virus-infected patient. Clinicians caring for human
immunodeficiency virus-infected patients should be vigilant about monitoring patients with increasing
lymphadenopathy, prompting thorough diagnostic investigations when necessary.
Introduction
The Ebstein-Barr virus (EBV) is a member of the her-
pesviridae family. Even though most infections with
EBV go unnoticed, in some cases it can be associated
with the development of potentially serious conditions,
including infectious mononucleosis. EBV has been asso-
ciated with central nervous system (CNS) diseases
(encephalitis and meningitis), but rarely as a cause of
myelitis [1,2]. The pathogenesis of EBV-associated CNS
disorders is not completely understood. While acute
EBV myelitis is rare, its occurrence in patients who are
infected with human immunodeficiency virus (HIV) or
who have acquired immunodeficiency syndrome (AIDS)
is even more uncommon.
Multi-centric Castleman’s disease (MCD) is a systemic
disorder characterized by significant peripheral lympha-
denopathy and hepatosplenomegaly, as well as frequent
fevers, night sweats, fatigue and weight loss [3]. HIV-
infected individuals appear to be at an increased risk for
MCD [4]. MCD also is well known to have an associa-
tion with human herpes virus 8 (HHV-8) and Kaposi’s
sarcoma (KS) [5]. Although no standard of care has
been established, MCD is often treated with aggressive
systemic immunomodulatory therapy [6].
Case Presentation
A 43-year-old Caucasian man on anti-retroviral therapy
(lopinavir/ritonavi and emtricitabine/tenofovir) for HIV/
AIDS presented in September 2008 with a three-month
history of low grade fevers, night sweats, generalized
fatigue, lethargy, unintentional weight loss, and bilateral
lower extremity swelling. He had a CD4 count of 196
cells/mm
3, and a viral load of <50 copies/mL. He had
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nadir was 4 (0.6%) in February 2004 with high viremia,
175,671 copies/mL. After initiation of potent anti-retro-
viral therapy the HIV viral load has been undetectable
since October 2004.
Ap h y s i c a le x a mo fo u rp a t i e n tr e v e a l e dd i f f u s el y m -
phadenopathy in his cervical, axillary and inguinal areas,
splenomegaly, and pitting edema in both lower extremi-
ties. Computed tomography of his chest, abdomen and
pelvis demonstrated widespread mediastinal, hilar, axil-
lary, retro-peritoneal and pelvic lymphadenopathy, as
well as the splenomegaly. A laboratory workup revealed
a hemoglobin level of 8.5 mg/dL, a white blood cell
count (WBC) of 4,600 cells/μL, an albumin level of 2.5
mg/dL, and a Westergren sedimentation rate of 90 mm/
h r .Al o w e re x t r e m i t yD o p p l e rw a sn e g a t i v ef o rd e e p
venous thrombosis.
Histological examination of lymph node biopsy material
revealed marked plasma cell infiltration, and follicles that
were variable in appearance, from marked follicular hyper-
plasia to involution and dendritic cell hyperplasia (Figure
1). Immunohistochemical studies demonstrated HHV-8
positive (Figure 2), and plasmablastic foci associated with
an intense polytypic plasma cell infiltrate. These findings
were consistent with the diagnosis of MCD–plasma cell
variant. Our patient was discharged from the hospital and
was scheduled to start treatment for MCD.
Three weeks later our patient presented with lower
abdominal pain, urinary retention, and lower extremity
weakness. Neurological examination revealed bilaterally
reduced motor power (4/5) in all major muscle groups
in his lower extremities, along with a positive Babinski
sign on the right. Deep tendon reflexes were normal
bilaterally. An ultrasound of his pelvis demonstrated
bladder distention. A Foley catheter was inserted and 2
liters of urine was evacuated, with complete relief of
pain.
A Gadolinium magnetic resonance imaging (MRI) of
his spine was done to rule out spinal cord compression;
it revealed abnormal spinal cord signal intensity invol-
ving several cervical and thoracic segments, associated
with expansion of the cord and mild enhancement of
the areas of abnormal T2 signal (Figure 3). MRI of the
brain revealed a few patchy areas of abnormal T2 signal
in the peri-ventricular and pontine white matter.
Figure 1 Histological specimen of enlarged lymph node
stained with hematoxylin and eosin. Reveals marked plasma cell
infiltration, and follicles that were variable in appearance, from
marked follicular hyperplasia to involution and dendritic cell
hyperplasia.
Figure 2 Immunohistochemical study demonstrates HHV-8
positive.
Figure 3 Thoracic-lumbar spine MRI with gadolinium
enhancement. There is increased signal in the spinal cord and
lumbosacral roots on sagittal view.
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(CSF) contained an elevated WBC of 50 cells/mm
3, with
90% lymphocytes, and a high protein level of 243 mg/
dL; cytological analysis identified mature reactive lym-
phocytes with no evidence of lymphoma on flow cyto-
metry. Polymerase chain reaction (PCR) was positive for
EBV DNA in the CSF, but negative for HHV-8, cytome-
galovirus (CMV), herpes simplex virus (HSV) and Vari-
cella-Zoster virus (VZV). Treatment with high-dose
dexamethasone was initiated. Our patient was then
transferred to the National Institute of Health (NIH)
and started on a treatment protocol of high-dose zido-
vudine (AZT) and valganciclovir for MCD (Clinical-
Trials.gov identifier: NCT00099073). Subsequent
laboratory follow-up revealed marked improvement over
the first seven days of treatment, including a marked
decrease in WBC and protein in his CSF. A follow-up
MRI demonstrated resolution of all spinal cord lesions.
He is now doing well, his last CD4 was 322 (15%), viral
load < 50 copies/mL in August 2010.
Discussion
This case is notable for two reasons. First, a 43-year-old
man with AIDS initially suspected to have lymphoma
due to his clinical features at presentation, was subse-
quently diagnosed with MCD. Second, within three
weeks he presented with EBV myelitis.
With respect to the former condition, this case brings
to light the importance of obtaining definitive histologi-
cal diagnoses in HIV-infected patients who present with
lymphadenopathy and systemic symptoms. MCD is rela-
tively uncommon cause for such a presentation. Though
clinically similar to lymphoma, MCD is an entity that is
distinct from malignant lymphoproliferative disorders in
both histology and prognosis. It is characterized by sig-
nificant peripheral lymphadenopathy and hepatospleno-
megaly, as well as by frequent fevers, night sweats,
fatigue and weight loss [7]. Abnormal laboratory find-
ings include pancytopenia, elevated liver function tests,
raised C-reactive protein and interleukin-6 (IL-6), and
hypergammaglobulinemia [3,8]. The condition typically
presents in patients between the ages of 50 and 65
years, but HIV-infected patients tend to be younger at
presentation, as in our case, and can be at an increased
risk for MCD [4,9]. This disease often arises concur-
rently with KS. It has been reported that, among HIV-
positive patients with MCD who are infected with
HHV-8, up to 70 percent will develop KS at some time
during their clinical course. MCD may present at any
CD4 count in these patients [4].
Although no standard treatment has been established,
MCD often is treated systemically [6] with such aggres-
sive remission-induction chemotherapy regimens as
cyclophosphamide-doxorubicin-vincristine-prednisone
(CHOP) and doxorubicin-bleomycin-vincristine; immu-
nomodulatory agents like thalidomide and interferon
alpha; and monoclonal antibodies, like those directed
against the IL-6 receptor (atlizumab) and CD20 (rituxi-
mab) [10,11]. The contribution of aggressive anti-retro-
viral treatment to the treatment of MCD remains
controversial. Novel treatments targeted at HHV-8 have
yielded promising results. Our patient was enrolled in
an NIH clinical trial of high-dose oral zidovudine and
valganciclovir for MCD ClinicalTrials.gov identifier:
NCT00099073.
EBV is a g-herpes virus that is detectable in over 90
percent of the general population. Even though most
infections with EBV go unnoticed, in some cases it can
be associated with the development of serious condi-
tions, including infectious mononucleosis. EBV has been
associated with CNS diseases, including meningitis and
encephalitis [1,2]. EBV myelitis is uncommon, but is
important in the differential diagnosis of acute myelopa-
thy. Acute EBV myelitis can present as neurologic dys-
function due to involvement of the white matter. When
EBV infection affects only part of the transverse expanse
of the spinal cord, it manifests as asymmetric motor and
sensory symptoms. The pathogenesis of EBV-associated
CNS disorders is not completely understood, but may
be due to direct viral invasion of the CNS. Alternatively,
damage may be immunologically-mediated via the infil-
tration of cytotoxic CD8+ lymphocytes into neural tis-
sue, or the deposition of antibody-antigen complexes
[1]. EBV infection may cause mild symptoms of mono-
nucleosis, like pharyngitis, prior to the onset of acute
myelitis [12].
Patients with AIDS have 10 to 20 times as many cir-
culating EBV-infected B-cells as those who are healthy.
T-cells from patients with AIDS suppress EBV-infected
B-cells less effectively than do cells from normal con-
trols [13]. A decline in EBV-specific cytotoxic T-cells
and an elevated EBV viral load precedes the develop-
ment of EBV-associated non-Hodgkin’s lymphomas in
HIV-infected patients; however, these changes are not
seen in patients with HIV before the development of
opportunistic infections. HIV viral load and the progres-
sion of HIV disease do not appear to be affected by pri-
mary infection with EBV [14].
In our patient, both the clinical and radiological find-
ings were characteristic of myeloradiculopathy. The CSF
abnormalities further indicated that the disease was
inflammatory. Extensive virological analysis of serum
and CSF revealed the presence of EBV DNA in the CSF,
as well as the absence of CMV, HSV, VZV and HHV-8.
The clinical features of myelitis, and the increased signal
in the cervical and thoracic spinal cord in this patient
on MRI, were similar to those described in previously
reported EBV myelitis cases [2,15-17].
Albany et al. Journal of Medical Case Reports 2011, 5:209
http://www.jmedicalcasereports.com/content/5/1/209
Page 3 of 4The International Herpes Management Forum recom-
mends that the diagnosis of EBV infections of the CNS
can include evidence of EBV DNA in CSF by PCR.
Unfortunately, there is no definitive treatment for EBV
infection of the nervous system. Steroids and immuno-
globulin have been used empirically, but their effects on
disease progression are unknown. Anti-viral therapy has
not demonstrated clinical efficacy in the treatment of
EBV-related CNS disorders [1].
Conclusions
Our patient presented with two rare disorders in rapid
succession, first MCD, followed by EBV myelitis. Histo-
logical evaluation revealed the first diagnosis, and CSF
PCR analysis the second. Clinicians caring for HIV-
infected patients should be vigilant about monitoring
patients with increasing lymphadenopathy, prompting
thorough diagnostic investigations when necessary.
Treatment for MCD can be complex, and referral to
dedicated programs with unique treatment protocols
should be considered. EBV myelitis is too rare for there
to be published therapeutic trials; nonetheless, systemic
steroids may be beneficial in its treatment.
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